Pharmacy Practice in Focus: Oncology
- July 2025
- Volume 7
- Issue 5
ASCO 2025: Pretreatment DPYD Testing for Fluoropyrimidines Can Improve Patient Safety and Lower Cost
Two abstracts from the American Society of Clinical Oncology (ASCO) annual meeting demonstrate that pretreatment DPYD genotyping improves the safety and cost-effectiveness of fluoropyrimidine chemotherapy, with oncology pharmacists playing a pivotal role in implementing and optimizing genotype-guided dosing strategies.
The landscape of pharmacogenomics in oncology is rapidly evolving, and recent findings presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting underscore the critical role of DPYD genotyping in optimizing the safety of fluoropyrimidine (FP)–based chemotherapy. Two abstracts from the Atrium Health Levine Cancer Institute provide compelling evidence on both the clinical outcomes and economic impact of pre-treatment DPYD testing in routine oncology practice.1,2